|
Market Closed -
Nasdaq
06:00:00 22/08/26 am AEST
|
5-day change | 1st Jan Change | ||
| 548.05 USD | +1.44% |
|
+8.36% | +20.89% |
| 13/08 | Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says | MT |
| 11/08 | Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
| 560.21 | +2.22% | 24 | |||||||
| 1,315.04 | +4.75% | 29 | |||||||
| 272.5 | +0.84% | 22 | |||||||
| 276.59 | +4.39% | 29 | |||||||
| 370.31 | -1.41% | 18 | |||||||
| 154.23 | -2.99% | 21 | |||||||
| 212.3 | +27.25% | 22 | |||||||
| 388.48 | -11.57% | 29 | |||||||
| 309.73 | +2.95% | 23 | |||||||
| 157.41 | +7.72% | 27 | |||||||
| 28.61 | +1.91% | 26 | |||||||
| 66.21 | -1.2% | 24 | |||||||
| 94.28 | +19.43% | 23 | |||||||
| 21.61 | +12.66% | 20 | |||||||
| 9,350 | +33.36% | 15 | |||||||
| 6,450.19 | +11.9% | 16 | |||||||
| 56.83 | +18.3% | 18 | |||||||
| 75.14 | +57.4% | 16 | |||||||
| 4.208 | +15.9% | 17 | |||||||
| 41.4 | +10.87% | 10 | |||||||
| Average | 1,010.26 | +10.73% | 21 | ||||||
| Weighted average by Cap. | 706.1 | +5.18% | 24 |
- Stock Market
- Stocks
- VRTX Stock
- Sector Vertex Pharmaceuticals Incorporated
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
















